久久评测

说话挑选:简体 / 繁體 / English

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

艰辛创业、诚信为本、开辟立异、严细守纪

山东罗欣药业团体股分无限公司投标通知布告

企业资讯

罗欣药业颁布发表与JW Holdings签订第三代三腔袋全肠外养分品独家开辟和谈

宣布时候:2020年10月26日 阅读次数:
分享:

罗欣药业团体股分无限公司(股票代码002793,简称“罗欣药业”)子公司山东罗欣药业团体股分无限公司明天上午经由过程云签约体例与韩国医药企业JW Holdings在线签订协作和谈。针对JW Holdings旗下第三代三腔袋全肠外养分品Winuf®,JW Holdings将授与罗欣药业在中国际地、香港出格行政区、澳门出格行政区开辟和商业化该产物的独家权利。今朝中国国际还没有含鱼油三腔袋全肠外养分品上市。据悉,JW Holdings为欧洲GMP认证的首个亚洲该类产物出产厂家。

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. , subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. (Stock Code: 002793, hereinafter referred to as "Luoxin Pharmaceutical"), signed an exclusive license and distribution agreement with JW Holdings through an online ceremony this morning. The agreement grants Luoxin Pharmaceutical the exclusive right to develop and commercialize Winuf® under JW Holdings in the Chinese mainland, Hong Kong and Macau. Winuf® is a three-chamber total parenteral nutrition (TPN) product and so far there are no commercialized TPN products containing refined fish oil on the Chinese market. Besides, JW Holdings is the first Asian TPN manufacturer certified by European GMP.

1.jpg

久久评测:在线签约典礼现场

Winuf®于2013年在韩国上市,并已进入欧洲市场。该产物含多种脂类物资、葡萄糖及氨基酸,合用于没法经由过程肠内路子摄取养分的患者、大剂量放化疗养分不良患者、严峻消化功效妨碍患者等人群。其精制鱼油含量跨越其余已上市三腔袋全肠外养分品规,可增进肝功效改良、增进人体脂代谢、有用抗炎并增进患者免疫力晋升与规复。该产物客岁在韩国国际发卖额冲破557亿韩元;据IQVIA数据显现,环球三腔袋全肠外养分品市场份额增加敏捷,2017-2019年环球市场年均增加率到达9.1%,中国市场年均增加率到达25.5%。

Launched in South Korea in 2013, Winuf® has also entered the European market. It consists of 4 lipid components, as well as glucose and amino acids. It’s suitable for patients who are not capable of enteral nutrition feeding, for malnutrition patients under high-dose radiotherapy or chemotherapy, and for patients with severe digestive dysfunction, etc. Winuf® contains a higher content of refined fish oil than other existing products, and promotes the improvement and recovery of immunity in patients. The domestic sales of Winuf® in South Korea were recorded as KRW 55.7 billion last year. According to IQVIA, the three-chamber TPN market is growing rapidly, with the average growth rate over the three years (2017-2019) of 9.1% globally and 25.5% in China.

按照和谈条目,罗欣药业将承当Winuf®在中国境内的临床研讨、注册和商业化相干勾当。JW Holdings将取得预支款,担任产物制作、供给,并按中国将来产物发卖额取得相干里程碑付款和特许利用权用度。JW Holdings首席履行官Sung Kwon Han表现:“咱们信任罗欣药业的临床研讨和商业化平台可以或许赞助咱们将Winuf®顺遂引进中国市场。咱们也但愿借此契机将Winuf®推向环球市场,并等候将来与罗欣药业拓展更多协作空间。”

According to the terms of the agreement, Luoxin Pharmaceutical will undertake the clinical research, registration and commercialization of Winuf® in China. JW Holdings will receive the upfront payment, be responsible for product manufacturing and supply of Winuf®, and obtain sales milestone and tiered-royalties from Luoxin Pharmaceutical based on future sales in China. “We believe that Luoxin Pharmaceutical's platform of clinical research and commercialization can help us successfully introduce Winuf® into the Chinese market. We also hope to take this opportunity to promote the global opportunities of our product, and look forward to expanding our cooperation with Luoxin Pharmaceutical in the future, "said Sung Kwon Han, CEO of JW Holdings.

“咱们很欢快与JW Holdings告竣此项协作和谈,也等候相干产物尽快进入中国市场并造福相干顺应症患者。” 罗欣药业董事长刘振腾表现,“公司最近几年来与多家韩国企业协作,联袂增进多种优异的产物和疗法进入中国。咱们将持续对峙自立与协作研发的双轨形式,打造更多可以或许承受市场磨练的潜力管线,为客户、病患和社会各界缔造最大的所需代价空间!”

"We are very pleased to reach agreement with JW Holdings. We hope Winuf® will enter the Chinese market and benefit patients with relevant indications as soon as possible," said Ryan Liu, CEOof Luoxin Pharmaceutical. "In recent years, Luoxin Pharmaceutical has formed strategic partnerships with many Korean enterprises to introduce excellent products and therapies into China. We will attach equal importance to independent and cooperative R&D, create pipeline that can withstand the market test, and bring more value to customers, patients and the society! "

久久评测:对于JW Group

JW团体自1945建立以来,一向以尊敬性命和立异精力为理念拓展制药研发,引领韩邦本土市场,并于1959年开启韩国首个“5%葡萄糖”病院处理计划。

其旗舰子公司JW Pharmaceutical具有包含抗癌药物在内的各类立异药研发渠道。JW Life Science则是一家特地处置医用打针剂出产的子公司,每一年出产和供给800万种综合养分素,该公司也具有环球最大的环保非PVC医用打针剂工场。

JW控股除办理子公司以外,还间接担任团体原资料、药品和医疗东西的海内营业。JW Holdings在韩邦交易所上市,股票代码为“096760”。

久久评测:About JW Group

JW Group has been leading the Korean market for therapeutic drugs based on respect for life and the founding philosophy of pioneering spirit since its foundation in 1945. In 1959, the nation's first medical hospital solution, "5% glucose," has started its local manufacture.

JW Pharmaceutical, its flagship subsidiary, has various innovative new drug R&D pipelines, including anti-cancer drugs, while JW Life Science, a subsidiary specializing in hospital injection production, produces and supplies 8 million comprehensive nutrients annually based on the world's largest plant dedicated to eco-friendly Non-PVC hospital injections.
 JW Holdings is also directly responsible for overseas business of raw materials, drugs and medical devices in the group, in addition to managing subsidiaries, generating profits. JW Holdings is listed on the Korean exchange as '096760'.

久久评测: 对于罗欣药业

罗欣药业团体股分无限公司(以下简称“罗欣药业”)是集药品研发、出产、商业及医疗安康办事为一体的大型医药企业团体。跻身成长速率抢先的中国制药企业方阵,罗欣药业努力于为客户供给高品德质料药、多剂型药物(片剂、胶囊剂、打针剂等)和医疗安康办事。

罗欣药业持续多年位列中国制药产业百强企业榜单,且屡次被评为“制药企业研发气力20强”,已于2019年登岸中国A股市场,股票代码002793。

久久评测:About Luoxin Pharmaceutical

Luoxin Pharmaceutical Group Stock Co., Ltd. is a healthcare conglomerate corporation in China that is engaged in pharmaceutical research and development, manufacture, sales, and healthcare service. As one of the fastest growing pharmaceutical companies in China, it serves customers with high quality active pharmaceutical ingredients (APIs), finished products in various formulation forms (tablets, capsules, injectable, etc.), and healthcare service.

Now the company has been ranking top 100 of China's Pharmaceutical Industry in terms of overall competence nationwide, and identified as one of the “Top 20 Pharmaceutical Companies with Strong R&D Pipelines” for years. The company was listed on China's A-shares market in 2019 as ‘002793’.

久久评测: